These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38885882)

  • 1. Reply to: "Mycophenolate mofetil in autoimmune hepatitis: Are we ready for primetime?".
    Slooter CD; Stoelinga AEC; Snijders RJALM
    J Hepatol; 2024 Oct; 81(4):e185-e186. PubMed ID: 38885882
    [No Abstract]   [Full Text] [Related]  

  • 2. Mycophenolate mofetil in autoimmune hepatitis: Are we ready for primetime?
    Biswas S; Shalimar
    J Hepatol; 2024 Oct; 81(4):e183-e184. PubMed ID: 38518975
    [No Abstract]   [Full Text] [Related]  

  • 3. Mycophenolate mofetil--a new treatment for autoimmune hepatitis?
    Dhawan A; Mieli-Vergani G
    J Hepatol; 2000 Sep; 33(3):480-1. PubMed ID: 11020006
    [No Abstract]   [Full Text] [Related]  

  • 4. Role of mycophenolate mofetil in the treatment of autoimmune hepatitis.
    Schramm C; Lohse AW
    J Hepatol; 2011 Sep; 55(3):510-511. PubMed ID: 21281682
    [No Abstract]   [Full Text] [Related]  

  • 5. Mycophenolate mofetil to the rescue in autoimmune hepatitis: a fresh sprout on the decision tree.
    Czaja AJ
    J Hepatol; 2009 Jul; 51(1):8-10. PubMed ID: 19446910
    [No Abstract]   [Full Text] [Related]  

  • 6. Histological changes after the use of mycophenolate mofetil in autoimmune hepatitis.
    Brunt EM; Di Bisceglie AM
    Hum Pathol; 2004 Apr; 35(4):509-12. PubMed ID: 15116334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes.
    Baven-Pronk AM; Coenraad MJ; van Buuren HR; de Man RA; van Erpecum KJ; Lamers MM; Drenth JP; van den Berg AP; Beuers UH; den Ouden J; Koek GH; van Nieuwkerk CM; Bouma G; Brouwer JT; van Hoek B
    Aliment Pharmacol Ther; 2011 Aug; 34(3):335-43. PubMed ID: 21668459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reply to: Comments on "An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis".
    Snijders RJALM; Stoelinga AEC; van Hoek B; Drenth JPH
    J Hepatol; 2024 Jul; 81(1):e43-e44. PubMed ID: 38554845
    [No Abstract]   [Full Text] [Related]  

  • 9. Autoimmune hepatitis: Mycophenolate mofetil vs. azathioprine as first-line therapy.
    Şimşek C; Wahlin S; Efe C
    J Hepatol; 2024 Jul; 81(1):e41-e42. PubMed ID: 38458322
    [No Abstract]   [Full Text] [Related]  

  • 10. Autoimmune hepatitis: Azathioprine or mycophenolate mofetil for inducing remission?
    Tiwari A; Khanikar D; Rathod SG
    J Hepatol; 2024 Jul; 81(1):e38-e39. PubMed ID: 38403031
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of mycophenolate in the treatment of autoimmune hepatitis.
    Oo YH; Neuberger J
    Liver Int; 2005 Aug; 25(4):687-91. PubMed ID: 15998416
    [No Abstract]   [Full Text] [Related]  

  • 12. Mycophenolate mofetil as a rescue therapy for autoimmune hepatitis patients who are not responsive to standard therapy.
    Fallatah HI; Akbar HO
    Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):517-22. PubMed ID: 21780898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate mofetil for the induction of remission in primary biliary cholangitis with predominant features of autoimmune hepatitis.
    Fan X; Yang F; Zhou L; Yang L
    J Hepatol; 2024 Jul; 81(1):e35-e36. PubMed ID: 38307344
    [No Abstract]   [Full Text] [Related]  

  • 14. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease.
    Czaja AJ; Carpenter HA
    J Clin Gastroenterol; 2005 Oct; 39(9):819-25. PubMed ID: 16145346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mycophenolate mofetil--a new therapeutic agent for chronic autoimmune diseases].
    Harboe E; Gøransson L; Wildhagen K; Omdal R
    Tidsskr Nor Laegeforen; 2005 Jun; 125(12):1650-2. PubMed ID: 15976831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy.
    Devlin SM; Swain MG; Urbanski SJ; Burak KW
    Can J Gastroenterol; 2004 May; 18(5):321-6. PubMed ID: 15152283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of immunosuppression in autoimmune hepatitis: A current literature review.
    Cropley A; Weltman M
    Clin Mol Hepatol; 2017 Mar; 23(1):22-26. PubMed ID: 28288505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of mycophenolate mofetil with standard treatment for autoimmune hepatitis: a meta-analysis.
    Yu ZJ; Zhang LL; Huang TT; Zhu JS; He ZB
    Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):873-877. PubMed ID: 31150366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis: new hope for difficult cases of autoimmune hepatitis.
    Halac U; Alvarez F
    Nat Rev Gastroenterol Hepatol; 2009 Nov; 6(11):629-30. PubMed ID: 19881512
    [No Abstract]   [Full Text] [Related]  

  • 20. Mycophenolate mofetil for patients with autoimmune hepatitis and overlap syndromes.
    García-Buey L; Moreno-Otero R
    Aliment Pharmacol Ther; 2011 Sep; 34(6):682-4; author reply 684-5. PubMed ID: 21851370
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.